Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on April 23, 2012, reporting an event that occurred on April 18, 2012. The company is incorporated in Nevada and is based in Englewood Cliffs, New Jersey.
Key Financial Metrics
The filing details a specific financing transaction rather than comprehensive financial statements.
- Debt Issuance: Sold a 10% senior secured convertible promissory note for a purchase price of $250,000.
- Interest Rate: 10% per annum.
- Conversion Terms: Convertible into common stock at an initial price of $1.50 per share.
- Repayment Source: Principal payments are tied to "Vendor Proceeds" (receipt of proceeds from sales to a certain vendor).
- Security: Secured by a first priority security interest in the Vendor Proceeds.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt, or overall liquidity positions.
Material Changes
The primary material change is the incurrence of new senior secured indebtedness. The company secured $250,000 in capital from an accredited investor. Additionally, certain existing holders of senior secured indebtedness agreed to subordinate their security interests in the Vendor Proceeds to the new investor.
Outlook, Risks, and Contingencies
- Repayment Contingency: The ability to repay the note is contingent upon the company generating proceeds from sales to a specific vendor.
- Acceleration Events: The entire remaining principal and accrued interest become due upon the Final Maturity Date, the consummation of a financing with net proceeds equal to or greater than 1.5 times the outstanding principal, or an Event of Default.
- Conversion Limitation: Conversion is prohibited if it would result in the investor beneficially owning more than 4.99% of the company's common stock (subject to waiver).
- Regulatory Status: The securities were sold unregistered under Section 4(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the identity of the "certain vendor" and the status of sales generating the "Vendor Proceeds" required for repayment.
- Confirm the total outstanding senior secured indebtedness prior to this transaction to understand the full capital structure.
- Review the definition of "Event of Default" in the attached Note (Exhibit 10.1) to assess immediate repayment risks.
- Check the current share count to calculate the potential dilution impact if the note is converted at $1.50 per share.